 Samir Jenkins
Concepts (130)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metal Nanoparticles | 4 | 2023 | 85 | 2.400 |
Why?
| | Gold | 6 | 2023 | 136 | 2.040 |
Why?
| | Nanostructures | 2 | 2023 | 47 | 1.420 |
Why?
| | Phototherapy | 3 | 2022 | 45 | 1.410 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 45 | 1.390 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2023 | 53 | 1.040 |
Why?
| | Lung Neoplasms | 4 | 2024 | 605 | 0.960 |
Why?
| | Bystander Effect | 1 | 2024 | 26 | 0.940 |
Why?
| | Neovascularization, Pathologic | 2 | 2022 | 162 | 0.890 |
Why?
| | beta-Glucosidase | 1 | 2022 | 4 | 0.860 |
Why?
| | Magnetite Nanoparticles | 1 | 2022 | 21 | 0.840 |
Why?
| | Endothelial Cells | 2 | 2022 | 270 | 0.830 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 114 | 0.810 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 154 | 0.800 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2021 | 21 | 0.750 |
Why?
| | Drug Delivery Systems | 3 | 2022 | 146 | 0.740 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.690 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 206 | 0.660 |
Why?
| | Preservation, Biological | 1 | 2018 | 9 | 0.650 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 78 | 0.650 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 128 | 0.640 |
Why?
| | Photosensitizing Agents | 2 | 2015 | 21 | 0.630 |
Why?
| | Neoplasms | 3 | 2024 | 1249 | 0.630 |
Why?
| | Animals | 12 | 2024 | 13246 | 0.610 |
Why?
| | Hyperthermia, Induced | 1 | 2019 | 117 | 0.600 |
Why?
| | Galectin 1 | 1 | 2017 | 21 | 0.570 |
Why?
| | Bacteria | 1 | 2018 | 222 | 0.570 |
Why?
| | Mice | 9 | 2024 | 5759 | 0.560 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 93 | 0.550 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 1186 | 0.540 |
Why?
| | Chlorophyll | 1 | 2015 | 11 | 0.520 |
Why?
| | Porphyrins | 1 | 2015 | 11 | 0.520 |
Why?
| | Blood | 1 | 2015 | 28 | 0.500 |
Why?
| | Nanoparticles | 3 | 2022 | 152 | 0.410 |
Why?
| | Models, Biological | 1 | 2015 | 723 | 0.410 |
Why?
| | Cell Line, Tumor | 5 | 2024 | 1416 | 0.400 |
Why?
| | Mice, Inbred BALB C | 4 | 2020 | 305 | 0.360 |
Why?
| | Radiotherapy | 2 | 2021 | 127 | 0.350 |
Why?
| | Apoptosis | 2 | 2024 | 1112 | 0.310 |
Why?
| | Radiation Tolerance | 2 | 2019 | 85 | 0.290 |
Why?
| | Spectrum Analysis, Raman | 2 | 2019 | 58 | 0.280 |
Why?
| | Benzeneacetamides | 1 | 2024 | 13 | 0.240 |
Why?
| | Glutaminase | 1 | 2024 | 19 | 0.240 |
Why?
| | Nanomedicine | 1 | 2024 | 21 | 0.240 |
Why?
| | Buthionine Sulfoximine | 1 | 2024 | 14 | 0.230 |
Why?
| | Endocytosis | 1 | 2024 | 63 | 0.230 |
Why?
| | Carboplatin | 1 | 2024 | 53 | 0.230 |
Why?
| | Endothelium | 2 | 2022 | 39 | 0.230 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2022 | 63 | 0.220 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 747 | 0.220 |
Why?
| | Enzymes, Immobilized | 1 | 2022 | 4 | 0.210 |
Why?
| | Silicon Dioxide | 1 | 2022 | 17 | 0.210 |
Why?
| | Doxorubicin | 1 | 2024 | 239 | 0.210 |
Why?
| | Amines | 1 | 2022 | 41 | 0.210 |
Why?
| | Liposomes | 1 | 2022 | 53 | 0.210 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 408 | 0.200 |
Why?
| | Cisplatin | 1 | 2024 | 278 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 1 | 2022 | 105 | 0.200 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 314 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 1 | 2022 | 188 | 0.190 |
Why?
| | Kidney Neoplasms | 1 | 2022 | 176 | 0.190 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2023 | 193 | 0.190 |
Why?
| | Humans | 13 | 2024 | 50208 | 0.180 |
Why?
| | Optical Imaging | 2 | 2017 | 25 | 0.170 |
Why?
| | Liver Neoplasms | 1 | 2023 | 328 | 0.170 |
Why?
| | Specimen Handling | 1 | 2018 | 55 | 0.160 |
Why?
| | Immunotherapy | 1 | 2020 | 240 | 0.160 |
Why?
| | Feces | 1 | 2018 | 131 | 0.150 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 56 | 0.150 |
Why?
| | Indazoles | 1 | 2018 | 46 | 0.150 |
Why?
| | Temperature | 1 | 2018 | 168 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 388 | 0.150 |
Why?
| | Bacterial Infections | 1 | 2018 | 96 | 0.140 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 233 | 0.140 |
Why?
| | Disease Progression | 1 | 2019 | 831 | 0.140 |
Why?
| | Epithelial Cells | 1 | 2018 | 207 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 318 | 0.130 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 386 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 273 | 0.130 |
Why?
| | Surface Properties | 1 | 2015 | 72 | 0.130 |
Why?
| | Spectrophotometry, Atomic | 1 | 2015 | 3 | 0.130 |
Why?
| | Citrates | 1 | 2015 | 11 | 0.130 |
Why?
| | Scattering, Radiation | 1 | 2015 | 31 | 0.130 |
Why?
| | Microscopy | 1 | 2015 | 57 | 0.120 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 196 | 0.120 |
Why?
| | Cell Membrane | 1 | 2015 | 251 | 0.120 |
Why?
| | Kinetics | 1 | 2015 | 631 | 0.120 |
Why?
| | Photochemotherapy | 1 | 2014 | 34 | 0.110 |
Why?
| | Ions | 2 | 2024 | 33 | 0.110 |
Why?
| | Cell Survival | 2 | 2024 | 602 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2022 | 636 | 0.080 |
Why?
| | Organelles | 1 | 2024 | 20 | 0.060 |
Why?
| | Thiadiazoles | 1 | 2024 | 19 | 0.060 |
Why?
| | MCF-7 Cells | 1 | 2024 | 69 | 0.060 |
Why?
| | Materials Testing | 1 | 2024 | 58 | 0.060 |
Why?
| | Particle Size | 1 | 2024 | 80 | 0.060 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2024 | 140 | 0.060 |
Why?
| | Biocompatible Materials | 1 | 2024 | 69 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2024 | 81 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2023 | 27 | 0.060 |
Why?
| | Glutamine | 1 | 2024 | 171 | 0.050 |
Why?
| | Halogens | 1 | 2022 | 4 | 0.050 |
Why?
| | Phosphatidylethanolamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Lipid Bilayers | 1 | 2022 | 13 | 0.050 |
Why?
| | Chloral Hydrate | 1 | 2022 | 19 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2022 | 95 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2022 | 163 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2020 | 1458 | 0.050 |
Why?
| | Heating | 1 | 2022 | 7 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 182 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2022 | 106 | 0.050 |
Why?
| | Protons | 1 | 2022 | 69 | 0.050 |
Why?
| | Female | 2 | 2020 | 26635 | 0.050 |
Why?
| | Cholesterol | 1 | 2022 | 147 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 202 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2022 | 266 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2024 | 1013 | 0.040 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2018 | 5 | 0.040 |
Why?
| | Inflammation | 1 | 2022 | 604 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 254 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 212 | 0.040 |
Why?
| | NAD | 1 | 2018 | 43 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 468 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2018 | 166 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 320 | 0.040 |
Why?
| | Glycolysis | 1 | 2017 | 70 | 0.040 |
Why?
| | Biofilms | 1 | 2018 | 181 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 75 | 0.030 |
Why?
| | Photoacoustic Techniques | 1 | 2014 | 72 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2014 | 5155 | 0.010 |
Why?
|
|
Jenkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|